Expanding products according to international standards to serve Vietnamese people and accelerating the export channel are two main pillars that help Hau Giang Pharmacy become more and more integrated with the advanced level of the global pharmaceutical and health care industry.
March 17th, 2021, the Primer Minister approved the program to develop the pharmacy industry and medical materiels produced in the country by 2030 with a vision to 2045. The programe aims to bring the domestic pharmaceutical industry to a high level of development, level 4 according to the classification scale of the World Health Organization (WHO), with a market value in the top 3 ASEAN. This is a farovable condition for many pharmaceutical industry enterprises not only keep the domestic market but also create momentum to enter the period increasingly deep intergration and conquer consumers by global standards.
During the past 47 years, DHG Pharma has always been one of the leading brands in the supply of international quality pharmaceuticals and healthcare products. During its development, DHG Pharma constantly improves product quality by increasing the number of production lines meeting international standards. In addition, DHG Pharma also "shakes hands" with a strategic partner, Taisho Pharmaceutical Group (Japan's top pharmaceutical company), to transfer technology from process to product quality to produce invention drugs, drugs of high economic value.
Most recently, in April, with the transfer of production technology from Taisho Group, DHG Pharma officially produced and distributed Counterpain - Skin Pain Relief Cream in Vietnam market. This is a product that has been presented in the international market for nearly 50 years, trusted by Southeast Asian consumers.
Mr Tran Duy Hung, Marketing Director, DHG said that, Counterpain products, manufactured by a leading pharmaceutical company in Vietnam combined with production technology of Japan, will help Vietnamese consumers easily find, buy and use with peace of mind, no longer having to worry about the origin and quality of products.
According to the report of Vietnam Report (Vietnam Assessment Report Joint Stock Company), the growth prospect of the pharmaceutical industry in 2022 will have many positive signals. The place for the domestic market and export of pharmaceuticals, health care products is still very large. Market research firm BMI Research (USA) also forecasts that the size of Vietnam's pharmaceutical market will reach $7.7 billion in 2021 and $16.1 billion in 2026, with a compound growth rate of up to 11 percents in VND and will continue to be in the group of 20 countries with the strongest and most stable growth in the world.
In addition, VIRAC and EvaluatePharma said that the compound growth rate of world drug market in the period 2020 - 2026 is about 7.4% and sales in 2026 will reach 1.39 billion USD, much higher than the rate 2.7% in the period 2012 - 2019. This is place for new suppliers, including Vietnam, to increase their contribution to the global market.
By taking steps in line with the trend of international integration, with investment in researching new drugs and expanding drug production lines to meet international standards of the drug and functional food market, DHG Pharma confidently places the 2022 revenue target is over 4,200 billion VND.
With increasing position and efforts in many different segments, DHG Pharma is increasingly enhancing the image one of the pharmaceutical enterprises with the heart and vision in comprehensive care of the Vietnamese people's health.
